Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Marciniec, Michał" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    Current Highlights in the Use of Magnetic Resonance Spectroscopy in Multiple Sclerosis
    Autorzy:
    Kulczyński, Marcin
    Walicka, Alicja
    Marciniec, Michał
    Sapko, Klaudia
    Dyndor, Katarzyna
    Powiązania:
    https://bibliotekanauki.pl/articles/1058090.pdf
    Data publikacji:
    2019
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Multiple sclerosis
    N-acetylaspartate
    brain metabolites
    demyelination
    magnetic resonance imaging
    magnetic resonance spectroscopy
    Opis:
    Magnetic resonance spectroscopy is a non-invasive method used to measure concentrations of selected metabolites in brain such as: N-acetylaspartate, creatine, choline, glutamic acid, myo-inositol, lactic acid or γ-aminobutyric acid. The MRS allows the researcher to obtain information about biochemical composition in selected localizations of the examined CNS and is based on the interpretation of spectra of specific chemical compounds. The aim of this study is a literature review of papers from last 5 years involving the use of MRS in multiple sclerosis. Magnetic resonance spectroscopy is a modern, promising metabolomic imaging method enabling the assessment of brain metabolite concentrations and the dynamism of their changes in healthy people and patients suffering from multiple sclerosis at every stage of the disease. MRS is helpful not only in correlating changes in metabolite concentrations at various central nervous system locations with clinical manifestations, but is also an increasingly improving tool for predicting disease progression. Magnetic resonance spectroscopy may also be useful in more specific clinical situations such as differential diagnosis between multiple sclerosis and Devic’s syndrome or between tumefactive demyelinating lesions and gliomas. Especially in the latter case, the development of this technology may in the future result in the possibility of avoiding invasive biopsy in patients during the diagnosis of focal changes in the CNS. One should also not forget about the role that MRS may play in the future in monitoring the course of treatment with modern MS drugs, not only in everyday clinical practice but also at the stage of clinical trials. The development of fast MRS techniques, significantly shortening the acquisition time and 7 T magnetic resonance spectroscopy, precise and repeatable method of quantitative analysis of brain metabolites may be particularly helpful in achieving these goals.
    Źródło:
    World Scientific News; 2019, 134, 2; 187-197
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Progressive forms of multiple sclerosis: disease-modifying therapy review
    Autorzy:
    Sapko, Klaudia
    Szczepańska-Szerej, Anna
    Jamroz-Wiśniewska, Anna
    Kulczyński, Marcin
    Marciniec, Michał
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1167060.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    Disease-modifying drugs
    Multiple sclerosis
    New therapy
    Primary-progressive MS
    Secondary-progressive MS
    Opis:
    Multiple sclerosis (MS) is a demyelinating, inflammatory, autoimmune disease of the central nervous system which affects most commonly young adults. It has wide spectrum of clinical and radiological presentations with relapses or steady progression. Recent years have brought new reports on the pathogenesis of MS. This systematized the current MS classification and created new parameters describing the course of the disease, such as activity and progression. Attention has been paid to the need for new drugs that focus on the treatment of progressive MS. Until now, the primary and secondary progressive MS have been somewhat forgotten, and most of modifying-disease drugs have been registered in the treatment of relapsing-remitting subtype. In recent years, not only new drug has been registered for the treatment of progressive MS (ocrelizumab) and another one is planned to be approved soon (siponimod), but also indications of old medicines (interferon-beta1b, cladribine, mitoxantrone, cyclophosphamide, azathioprine) have been extended. Despite intensive development, there is still a great need to seek new drugs that will stop the progression of disability in MS patients.
    Źródło:
    World Scientific News; 2018, 105; 157-167
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Radiologically Isolated Syndrome – a not so rare prelude to Multiple Sclerosis
    Autorzy:
    Kulczyński, Marcin
    Sapko, Klaudia
    Papuć, Ewa
    Marciniec, Michał
    Dyndor, Katarzyna
    Pankowska, Anna
    Pietura, Radosław
    Rejdak, Konrad
    Powiązania:
    https://bibliotekanauki.pl/articles/1164263.pdf
    Data publikacji:
    2018
    Wydawca:
    Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
    Tematy:
    biomarkers
    cerebro-spinal fluid
    cognitive impairment
    demyelinating diseases
    disability
    headache
    magnetic resonance imaging
    multiple sclerosis
    neurological disorders
    radiologically isolated syndrome
    Opis:
    Radiologically isolated syndrome (RIS) was defined for the first time in 2009 with an attempt to establish objective criteria of diagnosis for the patients, who underwent brain MRI scanning for a reason other than multiple sclerosis (MS), but were found to have white matter lesions in their central nervous systems (CNS) similar to those present in patients with diagnosed MS. RIS has been defined as separate entity with the presence of MRI findings strongly suggestive of MS in a patient with no neurological manifestations or other clear-cut explanation. Healthy patients may have an initial MRI procedure performed due to different reasons other than suspicion of MS, mainly because of headaches. However, a clinical examination does not reveal any signs of focal neurological deficits and there are no evidence for the focal damage in the CNS in these patients as well. Although RIS is not the first stage of multiple sclerosis in every patient, 30 up to even 45% of individuals diagnosed with this condition will present clinical symptoms in the future, within median time from 2.3 to 5.4 years depending on various researches. Most authors agree, that about 1/3 of patients with RIS will convert to clinically definite MS within 5 years of follow-up. There are some significant predictors of conversion, among others - presence of lesions in cervical and thoracic spinal cord. Moreover, patients with RIS, although asymptomatic in the meaning of classic clinical presentation of MS, are proved to experience early axonal loss, brain atrophy, increased anxiety and depression and subclinical inflammatory disease, as well as some signs of cognitive impairment. In this article we aim to make a review of the newest papers published in 2017 and 2018 concerning Radiologically Isolated Syndrome.
    Źródło:
    World Scientific News; 2018, 107; 1-11
    2392-2192
    Pojawia się w:
    World Scientific News
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies